Clinical Trial

Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Study acronym: PARTNER
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated November 14, 2022 (before its estimated June 2024 completion). Its status may not reflect the trial's current state.
Summary
This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with olaparib an inhibitor of the PARP enzyme (PARPi).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2017-05-10.
Trial Details
NCT Number NCT03150576
Lead Sponsor Cambridge University Hospitals NHS Foundation Trust
Collaborators: AstraZeneca, Cancer Research UK
Conditions Breast Cancer
Enrollment 780 participants
Start Date 2016-05
Primary Completion 2024-06 (estimated)
Study Completion 2034-06 (estimated)
Updated on ClinicalTrials.gov 2022-11-14